Fig. 5From: Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinibPFS according to the mutation in pathways frequently mutated in HCC patients. PFS according to the VAFmean of PI3K/MTOR pathway (A), WNT pathway (B), chromatin remodeling (C), cell cycle control (D), and telomere maintenance (E) at baselineBack to article page